Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide pilot study in adults with Prader-Willi syndrome
ACTRN12625000147482Phase 3Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of tirzepatide in Prader-Willi syndrome (PWS), sponsored by Sydney Local Health District. Primary endpoints: Gastric emptying, Caecal arrival time and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on ACTRN12625000147482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000147482.